RA Drug Use Doubles in Young Patients

MARCH 01, 2005

An analysis by Medco Health Solutions found that the number of children aged 19 and younger taking specialty drugs to treat rheumatoid arthritis (RA) has soared by 133% in the past 2 years, and spending on these medications has grown by 160%. The analysis, which compared the prescription data of children aged 19 and younger over the first 6 months of 2004 with the same time period in 2002, indicated that the rate of increase of spending on RA drugs for children has exceeded that of human growth hormone therapy.

Furthermore, spending on RA specialty medications is now higher than for any other biotech category. For example, for the first time, RA drugs have surpassed multiple sclerosis drugs. RA specialty medications have also shown the greatest increase in costs, making up 44% of the drug trend for the whole specialty category in 2004.


Become a Respimat Top Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc. 

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today? 


Pharmacy Times Strategic Alliance

Pharmacist Education
Clinical features with downloadable PDFs

Next-Generation Pharmacist® Awards

3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference

Personalize the information you receive by selecting targeted content and special offers.